drugset / Trial / NCT03904498
COMT Inhibition Among Individuals With Comorbid AUD/ADHD
Phase 2
Completed
23 enrolled
University of Colorado, Denver
National Institute on Alcohol Abuse and Alcoholism (NIAAA) · collab
RandomizedCrossoverDouble-blindBasic science
Summary
The purpose of this study is to determine whether the catechol-O-methyltransferase (COMT) inhibitor tolcapone, relative to placebo, affects response to alcohol, decision-making, brain activation associated with alcohol cue reactivity, response inhibition, and selective attention, or alcohol drinking.
Timeline
- Start
- 2021-08-16
- Primary completion
- 2026-03-09
- Completion
- 2026-03-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tolcapone | Unknown | 600 mg | — |